prikaz prve stranice dokumenta Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
Laboratory Medicine, 55 (2023), 2; 162-168. https://doi.org/10.1093/labmed/lmad044
Milevoj Kopcinovic, Lara; Unić, Adriana; Nikolac Gabaj, Nora; Miler, Marijana; Vrtaric, Alen; Bozovic, Marija; Stefanovic, Mario

Cite this document

Milevoj Kopcinovic, L., Unić, A., Nikolac Gabaj, N., Miler, M., Vrtaric, A., Bozovic, M. & Stefanovic, M. (2023). Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine, 55. (2), 162-168. doi: 10.1093/labmed/lmad044

Milevoj Kopcinovic, Lara, et al. "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines." Laboratory Medicine, vol. 55, no. 2, 2023, pp. 162-168. https://doi.org/10.1093/labmed/lmad044

Milevoj Kopcinovic, Lara, Adriana Unić, Nora Nikolac Gabaj, Marijana Miler, Alen Vrtaric, Marija Bozovic and Mario Stefanovic. "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines." Laboratory Medicine 55, no. 2 (2023): 162-168. https://doi.org/10.1093/labmed/lmad044

Milevoj Kopcinovic, L., et al. (2023) 'Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines', Laboratory Medicine, 55(2), pp. 162-168. doi: 10.1093/labmed/lmad044

Milevoj Kopcinovic L, Unić A, Nikolac Gabaj N, Miler M, Vrtaric A, Bozovic M, and sur.. Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine [Internet]. 2023 [cited 2024 November 17];55(2):162-168. doi: 10.1093/labmed/lmad044

L. Milevoj Kopcinovic, et al., "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines", Laboratory Medicine, vol. 55, no. 2, pp. 162-168, 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:075141. [Accessed: 17 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
AuthorLara Milevoj Kopcinovic
AuthorAdriana Unić
AuthorNora Nikolac Gabaj
AuthorMarijana Miler
AuthorAlen Vrtaric
AuthorMarija Bozovic
AuthorMario Stefanovic
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Biochemistry
Abstract (english)
Objective: To investigate the association of immune response with vaccination adverse effects at peak anti–receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria. Methods: Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested. Results: Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups. Conclusions: No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleLaboratory Medicine
Numberingvol. 55, no. 2, pp. 162-168
p-ISSN0007-5027
e-ISSN1943-7730
DOIhttps://doi.org/10.1093/labmed/lmad044
URN:NBNurn:nbn:hr:220:075141
Publication2023
Document URLhttps://academic.oup.com/labmed/article/55/2/162/7193314
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-07-15 13:54:09